KIORA PHARMACEUTICALS INC — Director's Dealing 2017

Nov 17, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2017-11-17

Reporting Person: Garanzini Michael (Chief Commercial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-17	Stock Option (right to buy)	$1.09	A	85000	Acquired	2027-11-17	Common Stock (85000)	Direct

Footnotes

F1: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on November 1, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.